Abstract

We report the design, synthesis, and in vitro antimicrobial activity of a series of N-substituted 3-aminopyrazine-2-carboxamides with free amino groups in position 3 on the pyrazine ring. Based on various substituents on the carboxamidic moiety, the series is subdivided into benzyl, alkyl, and phenyl derivatives. The three-dimensional structures of the title compounds were predicted using energy minimization and low mode molecular dynamics under AMBER10:EHT forcefield. Compounds were evaluated for antimycobacterial, antibacterial, and antifungal activities in vitro. The most active compound against Mycobacterium tuberculosis H37Rv (Mtb) was 3-amino-N-(2,4-dimethoxyphenyl)pyrazine-2-carboxamide (17, MIC = 12.5 µg/mL, 46 µM). Antimycobacterial activity against Mtb and M. kansasii along with antibacterial activity increased among the alkyl derivatives with increasing the length of carbon side chain. Antibacterial activity was observed for phenyl and alkyl derivatives, but not for benzyl derivatives. Antifungal activity was observed in all structural subtypes, mainly against Trichophyton interdigitale and Candida albicans. The four most active compounds (compounds 10, 16, 17, 20) were evaluated for their in vitro cytotoxicity in HepG2 cancer cell line; only compound 20 was found to exert some level of cytotoxicity. Compounds belonging to the current series were compared to previously published, structurally related compounds in terms of antimicrobial activity to draw structure activity relationships conclusions.

Highlights

  • Tuberculosis (TB) is a serious infection known for its lethality for centuries

  • As a part of our long-term project focused on structural modifications of PZA, we present the current series of twenty 3-aminopyrazine-2-carboxamides with various substituents on the carboxamidic nitrogen

  • N-substituted 3-aminopyrazine-2-carboxamide series is further subdivided based on the R substituent into eight benzyl derivatives, four alkyl derivatives, and eight phenyl derivatives (Figure 1)

Read more

Summary

Introduction

Tuberculosis (TB) is a serious infection known for its lethality for centuries. Despite the fact that the incidence of TB has been slowly decreasing since the beginning of the millennium, there are around 10 million new TB cases every year [1]. Since 2016, TB is the most common cause of death among all infectious diseases, followed by HIV [1]. The World Health Organization (WHO) has set a target to reduce the incidence of TB by 90% and the number of TB death cases by 95% by the year. TB-HIV co-infection and the emergence of multidrug-resistant mycobacterial strains constitute a growing risk that challenges the management of TB [3,4].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call